AndzonBio2 Partners with Cambridge to Tackle Neuroinflammation for Innovative Treatments
AndzonBio2 Collaborates with Cambridge for Neuroinflammation Treatments
On May 13, 2026, AndzonBio2 announced its new collaboration with the ALBORADA Drug Discovery Institute (ADDI) at the University of Cambridge and Cambridge Enterprise. This partnership aims to develop cutting-edge therapies targeting neuroinflammation, a significant contributor to numerous neurodegenerative diseases including Parkinson's, Alzheimer's, and Amyotrophic Lateral Sclerosis (ALS). The collaboration is particularly timely, as more than three billion individuals around the globe are affected by neurological disorders, often with limited effective treatments available.
Neuroinflammation has been increasingly recognized as a crucial biological driver in the progression of these diseases, making it a focal point for therapeutic innovation. This agreement combines AndzonBio2’s expertise in early-stage drug development with the extensive neuroscience capabilities of ADDI, leveraging advanced drug discovery technologies. The objective is to create an innovative therapeutic program aimed at modulating critical pathways involved in neuroinflammatory processes.
Loic Lhuillier, CEO of AndzonBio2, expressed his enthusiasm for the collaboration saying, “We are thrilled to partner with ADDI at Cambridge. Neuroinflammation is central to many severe brain diseases, and new therapeutic solutions are urgently needed. By combining our complementary strengths, we have a unique opportunity to accelerate the development of a highly innovative therapeutic approach that has the potential to change the treatment landscape for patients.”
The partnership will provide AndzonBio2 with an exclusive licensing option for the intellectual property generated through this collaborative effort. Moreover, the structure of this agreement aims to efficiently integrate academic research with quality industrial drug development, propelling swift progress towards candidate designation and future clinical trials.
Professor John Skidmore, Chief Scientist at the ALBORADA Drug Discovery Institute, also voiced his excitement, stating, “We are delighted to work with AndzonBio2 on this promising project. This partnership underscores our commitment to translating cutting-edge neuroscience into effective therapies. AndzonBio2 brings targeted expertise in neuroinflammation and drug development that will be pivotal in advancing this promising program.”
The collaboration is a step forward for both Cambridge and ADDI in their mission to catalyze innovation in neuroscience through partnerships that can result in tangible therapeutic opportunities.
About AndzonBio2
AndzonBio2 is a neuroscience-focused company structured to effectively transform scientific advancements into therapeutic solutions targeting the underlying causes of neurological diseases. Strategically focused on neuroinflammation, which is increasingly recognized as a critical component in multiple brain disorders, the company seeks to identify, evaluate, and integrate the most promising European projects. This effort aims to build and advance a leading portfolio balancing risk and benefit in neurology. For more information, visit www.andzonbio2.com.
About Cambridge Enterprise
Cambridge Enterprise connects and enables the transformation of Cambridge research into global impact. As the innovation arm of the University of Cambridge, it supports the application of Cambridge research to create substantial economic and social impact worldwide. From idea development to investment, they provide diverse support needed by researchers and innovators tackling today’s challenges. More information can be found at www.enterprise.cam.ac.uk.
About the ALBORADA Drug Discovery Institute
Financed by Alzheimer's Research UK and the ALBORADA Trust, the ALBORADA Drug Discovery Institute develops the next generation of treatments for diseases causing dementia. The ADDI bridges deep academic knowledge of diseases and the drug development capabilities of pharmaceutical and biotechnology industries, along with clinical excellence centers. Established as part of a broader initiative for drug discovery, funded by Alzheimer's Research UK and initiated in 2014, ADDI continues to build partnerships aimed at delivering impactful solutions for dementia-related illnesses.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.